JP2022533861A5 - - Google Patents
Info
- Publication number
- JP2022533861A5 JP2022533861A5 JP2022512708A JP2022512708A JP2022533861A5 JP 2022533861 A5 JP2022533861 A5 JP 2022533861A5 JP 2022512708 A JP2022512708 A JP 2022512708A JP 2022512708 A JP2022512708 A JP 2022512708A JP 2022533861 A5 JP2022533861 A5 JP 2022533861A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842800P | 2019-05-03 | 2019-05-03 | |
| US62/842,800 | 2019-05-03 | ||
| US201962880965P | 2019-07-31 | 2019-07-31 | |
| US62/880,965 | 2019-07-31 | ||
| US201962932651P | 2019-11-08 | 2019-11-08 | |
| US201962932654P | 2019-11-08 | 2019-11-08 | |
| US62/932,651 | 2019-11-08 | ||
| US62/932,654 | 2019-11-08 | ||
| PCT/US2020/031357 WO2020227233A2 (en) | 2019-05-03 | 2020-05-04 | Neoantigens in cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533861A JP2022533861A (ja) | 2022-07-26 |
| JPWO2020227233A5 JPWO2020227233A5 (https=) | 2023-05-16 |
| JP2022533861A5 true JP2022533861A5 (https=) | 2023-05-16 |
Family
ID=73050870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512708A Pending JP2022533861A (ja) | 2019-05-03 | 2020-05-04 | がんにおける新抗原 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220125900A1 (https=) |
| EP (2) | EP3963335B1 (https=) |
| JP (1) | JP2022533861A (https=) |
| CA (1) | CA3138867A1 (https=) |
| WO (1) | WO2020227233A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250232833A1 (en) * | 2024-01-13 | 2025-07-17 | Noergaard Anders Kaare | Cyclin D1 Based Cancer Vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008211227B2 (en) * | 2007-01-30 | 2014-04-17 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| BR112012029066A2 (pt) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| CN118750591A (zh) * | 2013-04-07 | 2024-10-11 | 博德研究所 | 用于个性化瘤形成疫苗的组合物和方法 |
| KR102841050B1 (ko) * | 2017-04-19 | 2025-08-01 | 그릿스톤 바이오, 인코포레이티드 | 신생항원 동정, 제조, 및 용도 |
| WO2020176726A1 (en) * | 2019-02-27 | 2020-09-03 | Epivax Oncology, Inc. | Improved compositions and methods for personalized neoplasia vaccines |
-
2020
- 2020-05-04 EP EP20729893.6A patent/EP3963335B1/en active Active
- 2020-05-04 WO PCT/US2020/031357 patent/WO2020227233A2/en not_active Ceased
- 2020-05-04 EP EP22208033.5A patent/EP4198513A1/en not_active Withdrawn
- 2020-05-04 JP JP2022512708A patent/JP2022533861A/ja active Pending
- 2020-05-04 CA CA3138867A patent/CA3138867A1/en active Pending
-
2021
- 2021-11-02 US US17/517,118 patent/US20220125900A1/en not_active Abandoned